FDA-cleared profile

Neurophet AQUA AD Plus

Neurophet., Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.

Clinical role
Segmentation, volumetric quantification and PET uptake quantification
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: Quantitative imaging support, not a standalone diagnosis. Each module has a distinct input and validation context; values and normative percentiles should not be assumed interchangeable with other software.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: DICOM 3D T1, T2-FLAIR and T2* GRE/SWI MRI and amyloid PET images.
  • Who uses it?Intended users: Qualified healthcare professionals, including physicians.
  • What does the software produce?Output: Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.
  • What is its most important limitation?Key limitation: Quantitative imaging support, not a standalone diagnosis. Each module has a distinct input and validation context; values and normative percentiles should not be assumed interchangeable with other software.

Clinical takeaway. Clinical role: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.

Evidence takeaway. Evidence from the reviewed source record: FDA summary describes module-specific independent validation datasets held separate from training data: 60 T1 MRI cases, 136 FLAIR cases, 30 paired MRI-PET datasets, 176 paired T1/PET scans for Centiloid classification, 100 edema-like FLAIR scans and 106 GRE/SWI scans. These are different tests, not one pooled clinical cohort.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Segmentation, volumetric quantification and PET uptake quantification
  • Exact FDA submission
  • Checked 2026-09-06
Required input
DICOM 3D T1, T2-FLAIR and T2* GRE/SWI MRI and amyloid PET images.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Baseline source-backed adult population retained; FDA validation describes approximately 40-80+ year old adults rather than all possible clinical use ages.

Intended users
Qualified healthcare professionals, including physicians.
  • Exact FDA submission
  • Checked 2026-09-01
Limitations
Quantitative imaging support, not a standalone diagnosis. Each module has a distinct input and validation context; values and normative percentiles should not be assumed interchangeable with other software.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
FDA summary describes module-specific independent validation datasets held separate from training data: 60 T1 MRI cases, 136 FLAIR cases, 30 paired MRI-PET datasets, 176 paired T1/PET scans for Centiloid classification, 100 edema-like FLAIR scans and 106 GRE/SWI scans. These are different tests, not one pooled clinical cohort.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA summary describes module-specific independent validation datasets held separate from training data: 60 T1 MRI cases, 136 FLAIR cases, 30 paired MRI-PET datasets, 176 paired T1/PET scans for Centiloid classification, 100 edema-like FLAIR scans and 106 GRE/SWI scans. These are different tests, not one pooled clinical cohort.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

The reviewed module validation reports segmentation, agreement and classification endpoints, not a single diagnostic sensitivity applicable across use cases.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

No single product-wide diagnostic specificity was established in the reviewed summary.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252496 T1-SegEngine validation

  • DesignStandalone segmentation comparison with expert manual segmentations
  • Population60 independent T1-weighted MRI cases
  • Scopeexact submission
  • Tested versionNeurophet AQUA AD Plus T1-SegEngine
  • Samplen=60
  • IndependenceSponsor or vendor study

K252496

K252496 FLAIR-SegEngine validation

  • DesignStandalone lesion-segmentation comparison with expert manual segmentations
  • Population136 independent T2-FLAIR cases
  • Scopeexact submission
  • Tested versionNeurophet AQUA AD Plus FLAIR-SegEngine
  • Samplen=136
  • IndependenceSponsor or vendor study

K252496

K252496 PET-Engine validation

  • DesignSUVR agreement comparison with an FDA-cleared reference product and Centiloid classification against consensus expert visual reads
  • Population30 paired MRI-PET datasets for SUVR; separate 176 paired T1 MRI/amyloid PET scans for Centiloid classification
  • Scopeexact submission
  • Tested versionNeurophet AQUA AD Plus PET-Engine
  • Samplen=30
  • IndependenceSponsor or vendor study

K252496

The 176-scan classification cohort is separate and is not combined with the 30-pair cohort.

K252496 lesion-segmentation validation

  • DesignStandalone segmentation comparison with expert manual segmentations
  • Population100 T2-FLAIR edema-like hyperintensity scans and separate 106 GRE/SWI hypointense-lesion scans
  • Scopeexact submission
  • Tested versionNeurophet AQUA AD Plus ED-SegEngine and HEM-SegEngine
  • Samplen=100
  • IndependenceSponsor or vendor study

K252496

Distinct ED and HEM cohorts; no pooled unique-patient total asserted.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

Downloaded exact-ID recall packet contained zero records; that limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 3D T1, T2-FLAIR and T2* GRE/SWI MRI and amyloid PET images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · Neurophet AQUA AD Plus: K252496 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Accepts DICOM input and produces DICOM results displayable at DICOM workstations and PACS.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · Neurophet AQUA AD Plus: K252496 clearance and 510(k) summary

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed FDA summary describes DICOM input/output but does not establish the complete commercial hosting, on-premise/cloud topology or upgrade workflow.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 ·

  4. Returned objects

    Source context, not route validation: Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · Neurophet AQUA AD Plus: K252496 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · Neurophet AQUA AD Plus: K252496 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Accepts DICOM input and produces DICOM results displayable at DICOM workstations and PACS.
  • Exact FDA submission
  • Checked 2026-09-06
Security
Neurophet announced on its press page and company history page that it obtained international information security certifications ISO 27001 and ISO 27701 (Korean-language pages).
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement (Korean-language press release headline and history entry on the owning domain); the press page body did not render readable text on 2026-10-27 and certificates were not read. Exact-release scope is not established.

DICOM interoperability

DICOM input and result output for DICOM workstations and PACS.

exact submission · checked 2026-09-06

Current vendor positioning

Vendor announcement positions MRI/PET quantitative analysis across Alzheimer-care evaluation; this is family context, not an independently verified outcomes claim.

product family · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252496
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

Controlled catalog category retained. The exact indication specifically uses MR plus PET images; it is not an unspecified-modality claim.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-29
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored literature-index and trial-registry candidate arrays were empty and screened. This does not assert that no literature or trials exist; no unscreened study is promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor announcement, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    No public U.S. list price, installation charge or license term was identified in reviewed primary sources.

  • Pricing model: Not verified - checked 2026-09-06 - Exact FDA submission

    Per-case, module, site and support-model terms remain unverified.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Neurophet AQUA AD Plus reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Results were Japan or Korea coverage news and vendor pages, not US coding or payment for this product. This records what was found, not that none exists.

  • Deployment: Not publicly available - checked 2026-09-06 - Exact FDA submission

    The reviewed FDA summary describes DICOM input/output but does not establish the complete commercial hosting, on-premise/cloud topology or upgrade workflow.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-06 - Exact FDA submission

    Current workflow training, reader qualification and support arrangements require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-06 - Exact FDA submission

    Public sources reviewed do not establish site-level production monitoring, update acceptance or incident escalation.

8 sources - 3 history items

Source ledger

  1. Neurophet AQUA AD Plus: K252496 clearance and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Neurophet AQUA AD Plus model card (K252496)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Neurophet AQUA AD Plus FDA-clearance announcement

    Neurophet - Published 2026-02-06 - Accessed 2026-09-06

    Scope: productFamilyContext, commercialAvailability

  8. Neurophet: ISO 27001 and ISO 27701 Certification Announcement

    Neurophet - Accessed 2026-10-27

    Scope: security

Research history

  1. K252496 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K252563

Neurophet SCALE PET

Neurophet., Inc.

Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-05-15
FDA-cleared K241083

SIS System

Surgical Information Sciences, Inc.

Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2024-06-14
FDA-cleared K230977

SIS System

Surgical Information Sciences, Inc.

Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, and GPi, and segment implanted leads for professional review.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2023-05-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history